Insider at FibroGen (FGEN) Makes Significant Sale of Stock

Wednesday, October 04, 2017 10:15 PM ET

Insider at FibroGen (FGEN) Makes Significant Sale of Stock

A substantial insider sale of the shares of FibroGen was disclosed in a form 4 document filed with the SEC today, showing — Thomas B Neff, Director and Officer — sold 38,636 shares in the company having a market value of approximately $2,128,314. There have been 5 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the sale of 126,474 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 165,110 shares and have averaged 27,518 shares per transaction over this time period.

Over the last 90 days, the number of insider buy/sell trades at FibroGen is above its 183-company peer group average. The Biotechnology & Medical Research peer group saw 220 buy/sell trades during this period for an average of 1.2 transactions per company. However, the number of shares traded per transaction by FibroGen insiders is lower than its peers. Within the peer group there were 8,599,879 shares purchased and 51,102,907 shares sold with company insiders having sold 193,196 shares on average over this time period.

The data obtained in composing and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at info@uptickdata.com. Copyright 2017 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.